Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Gammadelta T cells show potential for tumor immunotherapy based on mouse and human studies.
• Human gammadelta T cells activate via non-MHC dependent pathways, including phosphoantigens and pyrophosphate accumulation.
• Aminobisphosphonates are clinically used agents that induce pyrophosphate accumulation and possess antiangiogenic, antiosteolytic, and pro-apoptotic effects.

Purpose of the Study:

• To explore the potential of activating gammadelta T cells in vivo using aminobisphosphonates.
• To discuss the design of novel cancer immunotherapies targeting gammadelta T cells.

Main Methods:

• Review of existing literature on gammadelta T cell activation.
• Analysis of aminobisphosphonate properties and their effects on gammadelta T cells.
• Discussion of in vivo activation strategies for immunotherapy.

Main Results:

• Aminobisphosphonates can activate gammadelta T cells.
• These activated cells have potential anti-tumor properties.
• The mechanism involves non-MHC dependent activation pathways.

Conclusions:

• Intentional in vivo activation of gammadelta T cells by aminobisphosphonates is a promising strategy for innovative cancer immunotherapy.
• This approach may be applicable to diverse cancer types.
• Further research into this immunotherapy is warranted.